Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Gilead Sciences Inc., historical price multiples (quarterly data)
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Gilead Sciences Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Gilead Sciences Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then slightly increased from Q3 2020 to Q4 2020. |
Price to Earnings (P/E)
Gilead Sciences Inc., historical P/E calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 1,256,593,156 | 1,253,528,149 | 1,253,724,370 | 1,254,373,400 | 1,263,636,656 | 1,265,145,612 | 1,266,455,481 | 1,271,554,672 | 1,275,510,558 | 1,293,619,612 | 1,296,340,593 | 1,300,260,832 | 1,309,967,781 | 1,306,268,996 | 1,305,926,217 | 1,306,728,398 | 1,307,066,900 | 1,317,456,071 | 1,319,658,489 | 1,331,821,506 | ||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Net income (loss) attributable to Gilead (in millions) | 1,551 | 360 | (3,339) | 1,551 | 2,696 | (1,165) | 1,880 | 1,975 | 3 | 2,097 | 1,817 | 1,538 | (3,865) | 2,718 | 3,073 | 2,702 | 3,108 | 3,330 | 3,497 | 3,566 | ||||||
Earnings per share (EPS)2 | 0.10 | 1.01 | -0.20 | 3.96 | 4.26 | 2.13 | 4.70 | 4.63 | 4.28 | 1.23 | 1.70 | 2.66 | 3.53 | 8.88 | 9.35 | 9.67 | 10.33 | 0.00 | 0.00 | 0.00 | ||||||
Share price1, 3 | 62.79 | 59.87 | 68.81 | 77.47 | 70.10 | 65.39 | 63.98 | 66.07 | 65.28 | 70.35 | 77.87 | 65.69 | 80.36 | 73.21 | 73.44 | 66.92 | 70.50 | 74.00 | 80.41 | 84.68 | ||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/E ratio4 | 641.48 | 59.19 | — | 19.58 | 16.45 | 30.72 | 13.61 | 14.26 | 15.26 | 57.34 | 45.72 | 24.66 | 22.75 | 8.24 | 7.85 | 6.92 | 6.83 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
P/E Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | 48.49 | 58.45 | 58.36 | 45.61 | 41.83 | 44.92 | 53.17 | 52.98 | 56.47 | 136.66 | 122.73 | 213.07 | 220.29 | 45.00 | 73.04 | 50.48 | 55.16 | — | — | — | ||||||
AbbVie Inc. | 40.17 | 22.60 | 23.92 | 14.70 | 17.82 | 37.29 | 23.42 | 21.71 | 20.60 | 17.29 | 22.09 | 24.91 | 35.47 | 22.56 | 17.16 | 16.90 | 16.54 | — | — | — | ||||||
Amgen Inc. | 18.82 | 17.25 | 19.97 | 17.70 | 17.07 | 15.53 | 14.06 | 13.30 | 14.01 | 55.79 | 52.69 | 52.13 | 64.06 | 15.67 | 15.70 | 15.16 | 16.03 | — | — | — | ||||||
Bristol-Myers Squibb Co. | — | — | — | 144.77 | 41.99 | 16.53 | 11.97 | 14.51 | 16.81 | 56.09 | 251.38 | 92.56 | 103.55 | 23.59 | 19.40 | 18.96 | 20.56 | — | — | — | ||||||
Eli Lilly & Co. | 31.95 | 22.54 | 25.59 | 26.56 | 16.19 | 13.31 | 13.84 | 18.38 | 39.13 | 249.24 | — | 79.88 | — | 41.51 | 37.39 | 41.29 | 32.39 | — | — | — | ||||||
Illumina Inc. | 109.92 | 66.98 | 74.93 | 47.73 | 43.43 | 43.91 | 46.92 | 54.25 | 52.00 | 62.22 | 73.58 | 59.94 | 44.63 | 38.26 | 38.75 | 36.92 | 52.01 | — | — | — | ||||||
Johnson & Johnson | 28.92 | 22.51 | 25.68 | 23.06 | 25.99 | 24.03 | 21.50 | 25.68 | 23.74 | 243.48 | 256.64 | 271.47 | 268.10 | 23.75 | 21.91 | 20.12 | 20.08 | — | — | — | ||||||
Merck & Co. Inc. | 26.72 | 17.67 | 19.70 | 19.18 | 20.60 | 22.67 | 23.07 | 23.97 | 33.46 | 56.97 | 132.14 | 96.71 | 61.63 | 53.20 | 33.41 | 39.83 | 46.14 | — | — | — | ||||||
Pfizer Inc. | 19.62 | 23.29 | 15.01 | 13.00 | 11.63 | 12.60 | 16.12 | 19.69 | 21.58 | 10.64 | 10.66 | 9.43 | 9.99 | 21.39 | 23.88 | 27.02 | 28.10 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 15.09 | 19.91 | 22.27 | 28.35 | 19.86 | 17.03 | 15.94 | 14.56 | 18.17 | 21.53 | 26.96 | 22.09 | 28.99 | 34.90 | 43.35 | 47.93 | 42.64 | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 20.18 | 20.14 | 34.05 | 43.74 | 52.90 | 23.44 | 20.80 | 20.51 | 22.59 | 65.41 | 108.21 | 175.96 | 155.08 | 193.19 | 149.56 | 166.15 | — | — | — | — | ||||||
Zoetis Inc. | 48.25 | 48.84 | 47.41 | 37.05 | 45.89 | 39.46 | 42.08 | 35.57 | 28.68 | 38.90 | 39.51 | 39.53 | 44.09 | 35.00 | 33.42 | 33.79 | 31.63 | — | — | — |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
EPS
= (Net income (loss) attributable to GileadQ4 2020
+ Net income (loss) attributable to GileadQ3 2020
+ Net income (loss) attributable to GileadQ2 2020
+ Net income (loss) attributable to GileadQ1 2020)
÷ No. shares of common stock outstanding
= (1,551,000,000 + 360,000,000 + -3,339,000,000 + 1,551,000,000)
÷ 1,256,593,156 = 0.10
3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/E ratio = Share price ÷ EPS
= 62.79 ÷ 0.10 = 641.48
5 Click competitor name to see calculations.
Price to Operating Profit (P/OP)
Gilead Sciences Inc., historical P/OP calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 1,256,593,156 | 1,253,528,149 | 1,253,724,370 | 1,254,373,400 | 1,263,636,656 | 1,265,145,612 | 1,266,455,481 | 1,271,554,672 | 1,275,510,558 | 1,293,619,612 | 1,296,340,593 | 1,300,260,832 | 1,309,967,781 | 1,306,268,996 | 1,305,926,217 | 1,306,728,398 | 1,307,066,900 | 1,317,456,071 | 1,319,658,489 | 1,331,821,506 | ||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Income (loss) from operations (in millions) | 2,651 | 2,001 | (2,983) | 2,402 | 1,093 | (1,473) | 2,430 | 2,237 | 1,144 | 2,623 | 2,280 | 2,153 | 2,291 | 3,812 | 4,254 | 3,767 | 4,045 | 4,399 | 4,538 | 4,651 | ||||||
Operating profit per share2 | 3.24 | 2.00 | -0.77 | 3.55 | 3.39 | 3.43 | 6.66 | 6.51 | 6.43 | 7.23 | 8.13 | 9.62 | 10.78 | 12.16 | 12.61 | 12.82 | 13.49 | 0.00 | 0.00 | 0.00 | ||||||
Share price1, 3 | 62.79 | 59.87 | 68.81 | 77.47 | 70.10 | 65.39 | 63.98 | 66.07 | 65.28 | 70.35 | 77.87 | 65.69 | 80.36 | 73.21 | 73.44 | 66.92 | 70.50 | 74.00 | 80.41 | 84.68 | ||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/OP ratio4 | 19.38 | 29.86 | — | 21.83 | 20.66 | 19.07 | 9.61 | 10.14 | 10.15 | 9.74 | 9.58 | 6.83 | 7.45 | 6.02 | 5.82 | 5.22 | 5.23 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | 40.69 | 45.82 | 45.19 | 35.87 | 34.03 | 34.32 | 37.50 | 36.74 | 36.64 | 38.12 | 38.00 | 39.99 | 60.88 | 47.72 | 41.32 | 30.85 | 24.25 | — | — | — | ||||||
AbbVie Inc. | 16.32 | 14.42 | 15.23 | 9.13 | 10.82 | 18.43 | 13.53 | 17.93 | 18.35 | 12.32 | 14.01 | 15.78 | 19.63 | 14.77 | 11.57 | 11.19 | 10.49 | — | — | — | ||||||
Amgen Inc. | 14.96 | 13.82 | 15.84 | 14.22 | 13.84 | 12.52 | 11.35 | 10.73 | 11.46 | 12.13 | 12.16 | 11.45 | 12.71 | 12.55 | 12.46 | 11.99 | 12.64 | — | — | — | ||||||
Bristol-Myers Squibb Co. | — | 39.45 | 33.97 | 27.33 | 24.42 | 13.51 | 10.89 | 13.68 | 16.16 | 19.56 | 27.48 | 23.10 | 28.87 | 24.60 | 20.23 | 19.09 | 19.79 | — | — | — | ||||||
Eli Lilly & Co. | 32.66 | 22.98 | 25.58 | 24.82 | 27.08 | 23.37 | 23.99 | 38.43 | 33.99 | 37.45 | 47.62 | 25.86 | 39.61 | 33.07 | 29.23 | 32.37 | 25.63 | — | — | — | ||||||
Illumina Inc. | 124.33 | 59.77 | 60.31 | 46.36 | 44.17 | 46.74 | 51.96 | 53.12 | 48.64 | 46.46 | 55.70 | 44.02 | 53.47 | 57.62 | 58.10 | 52.79 | 40.99 | — | — | — | ||||||
Johnson & Johnson | 21.84 | 19.46 | 19.66 | 18.67 | 19.83 | 17.23 | 19.08 | 20.36 | 18.34 | 20.42 | 18.93 | 18.18 | 18.94 | 18.71 | 17.29 | 15.95 | 16.09 | — | — | — | ||||||
Merck & Co. Inc. | 23.89 | 16.00 | 17.23 | 15.88 | 17.47 | 17.97 | 18.21 | 19.17 | 25.08 | 25.60 | 34.95 | 27.63 | 22.58 | 38.37 | 25.21 | 30.01 | 33.62 | — | — | — | ||||||
Pfizer Inc. | 23.12 | 16.79 | 18.20 | 15.97 | 14.36 | 14.64 | 13.82 | 15.62 | 17.19 | 18.14 | 17.36 | 15.05 | 15.62 | 16.20 | 16.11 | 16.34 | 16.88 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 14.82 | 20.36 | 23.98 | 26.60 | 19.01 | 16.21 | 15.41 | 14.44 | 17.53 | 16.43 | 18.75 | 14.23 | 16.71 | 23.63 | 29.60 | 32.24 | 28.70 | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 19.16 | 20.35 | 33.91 | 40.27 | 51.98 | 64.96 | 52.36 | 56.45 | 74.57 | 66.84 | 442.93 | — | 331.55 | 1,018.05 | 112.83 | 99.84 | 2,143.58 | — | — | — | ||||||
Zoetis Inc. | 35.22 | 36.65 | 36.24 | 28.78 | 35.00 | 30.23 | 32.11 | 27.78 | 22.59 | 23.98 | 23.28 | 21.51 | 22.33 | 21.75 | 20.64 | 20.42 | 18.65 | — | — | — |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Operating profit per share
= (Income (loss) from operationsQ4 2020
+ Income (loss) from operationsQ3 2020
+ Income (loss) from operationsQ2 2020
+ Income (loss) from operationsQ1 2020)
÷ No. shares of common stock outstanding
= (2,651,000,000 + 2,001,000,000 + -2,983,000,000 + 2,402,000,000)
÷ 1,256,593,156 = 3.24
3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 62.79 ÷ 3.24 = 19.38
5 Click competitor name to see calculations.
Price to Sales (P/S)
Gilead Sciences Inc., historical P/S calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 1,256,593,156 | 1,253,528,149 | 1,253,724,370 | 1,254,373,400 | 1,263,636,656 | 1,265,145,612 | 1,266,455,481 | 1,271,554,672 | 1,275,510,558 | 1,293,619,612 | 1,296,340,593 | 1,300,260,832 | 1,309,967,781 | 1,306,268,996 | 1,305,926,217 | 1,306,728,398 | 1,307,066,900 | 1,317,456,071 | 1,319,658,489 | 1,331,821,506 | ||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Product sales (in millions) | 7,328 | 6,493 | 5,067 | 5,467 | 5,796 | 5,516 | 5,607 | 5,200 | 5,681 | 5,455 | 5,540 | 5,001 | 5,837 | 6,402 | 7,046 | 6,377 | 7,216 | 7,405 | 7,651 | 7,681 | ||||||
Sales per share2 | 19.38 | 18.21 | 17.42 | 17.85 | 17.50 | 17.39 | 17.33 | 17.20 | 16.99 | 16.88 | 17.57 | 18.68 | 19.59 | 20.70 | 21.47 | 21.92 | 22.92 | 0.00 | 0.00 | 0.00 | ||||||
Share price1, 3 | 62.79 | 59.87 | 68.81 | 77.47 | 70.10 | 65.39 | 63.98 | 66.07 | 65.28 | 70.35 | 77.87 | 65.69 | 80.36 | 73.21 | 73.44 | 66.92 | 70.50 | 74.00 | 80.41 | 84.68 | ||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/S ratio4 | 3.24 | 3.29 | 3.95 | 4.34 | 4.00 | 3.76 | 3.69 | 3.84 | 3.84 | 4.17 | 4.43 | 3.52 | 4.10 | 3.54 | 3.42 | 3.05 | 3.08 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
P/S Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | 6.30 | 6.13 | 5.77 | 5.09 | 4.83 | 4.72 | 4.98 | 4.52 | 4.37 | 3.98 | 3.84 | 3.57 | 3.84 | 3.77 | 3.62 | 3.40 | 3.70 | — | — | — | ||||||
AbbVie Inc. | 4.05 | 4.10 | 4.59 | 3.64 | 4.22 | 3.69 | 2.96 | 3.56 | 3.58 | 4.06 | 4.60 | 5.37 | 6.67 | 5.50 | 4.25 | 4.07 | 3.84 | — | — | — | ||||||
Amgen Inc. | 5.64 | 5.33 | 6.30 | 5.96 | 6.03 | 5.61 | 5.00 | 4.78 | 5.22 | 5.56 | 5.65 | 5.27 | 5.82 | 5.85 | 5.85 | 5.48 | 5.65 | — | — | — | ||||||
Bristol-Myers Squibb Co. | 3.16 | 3.66 | 3.97 | 4.45 | 5.52 | 3.87 | 3.11 | 3.21 | 3.67 | 3.64 | 4.38 | 4.04 | 5.02 | 4.85 | 4.40 | 4.59 | 4.72 | — | — | — | ||||||
Eli Lilly & Co. | 8.06 | 5.41 | 6.26 | 6.36 | 6.03 | 4.67 | 4.67 | 4.80 | 5.15 | 4.62 | 4.34 | 3.85 | 3.71 | 4.11 | 4.16 | 4.18 | 4.18 | — | — | — | ||||||
Illumina Inc. | 22.26 | 13.20 | 15.50 | 12.64 | 12.28 | 12.35 | 12.92 | 13.59 | 12.89 | 13.12 | 15.36 | 11.58 | 11.77 | 11.53 | 11.65 | 11.27 | 10.03 | — | — | — | ||||||
Johnson & Johnson | 5.15 | 4.73 | 4.84 | 4.78 | 4.79 | 4.16 | 4.32 | 4.62 | 4.45 | 4.61 | 4.36 | 4.29 | 4.56 | 5.06 | 4.93 | 4.60 | 4.62 | — | — | — | ||||||
Merck & Co. Inc. | 3.93 | 4.30 | 4.38 | 4.05 | 4.33 | 4.59 | 4.87 | 4.67 | 4.92 | 4.57 | 4.29 | 3.75 | 3.68 | 3.80 | 4.25 | 4.34 | 4.54 | — | — | — | ||||||
Pfizer Inc. | 4.50 | 4.16 | 4.32 | 4.05 | 3.66 | 3.85 | 3.80 | 4.20 | 4.49 | 4.75 | 4.51 | 3.89 | 4.05 | 4.00 | 3.80 | 3.75 | 3.84 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 6.24 | 7.62 | 8.31 | 8.10 | 5.34 | 4.79 | 4.56 | 5.11 | 6.62 | 6.08 | 6.92 | 5.20 | 5.92 | 8.09 | 9.56 | 9.27 | 7.86 | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 8.82 | 9.04 | 13.11 | 13.71 | 14.95 | 13.89 | 13.34 | 13.54 | 15.54 | 14.96 | 17.14 | 16.47 | 16.42 | 16.47 | 18.23 | 14.60 | 12.51 | — | — | — | ||||||
Zoetis Inc. | 11.84 | 12.42 | 12.09 | 9.42 | 11.00 | 9.37 | 9.57 | 8.35 | 7.03 | 7.92 | 7.88 | 7.10 | 7.18 | 6.40 | 5.85 | 5.83 | 5.31 | — | — | — |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
Sales per share
= (Product salesQ4 2020
+ Product salesQ3 2020
+ Product salesQ2 2020
+ Product salesQ1 2020)
÷ No. shares of common stock outstanding
= (7,328,000,000 + 6,493,000,000 + 5,067,000,000 + 5,467,000,000)
÷ 1,256,593,156 = 19.38
3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 62.79 ÷ 19.38 = 3.24
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Gilead Sciences Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Price to Book Value (P/BV)
Gilead Sciences Inc., historical P/BV calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 1,256,593,156 | 1,253,528,149 | 1,253,724,370 | 1,254,373,400 | 1,263,636,656 | 1,265,145,612 | 1,266,455,481 | 1,271,554,672 | 1,275,510,558 | 1,293,619,612 | 1,296,340,593 | 1,300,260,832 | 1,309,967,781 | 1,306,268,996 | 1,305,926,217 | 1,306,728,398 | 1,307,066,900 | 1,317,456,071 | 1,319,658,489 | 1,331,821,506 | ||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||
Total Gilead stockholders’ equity (in millions) | 18,202 | 17,445 | 18,027 | 22,067 | 22,525 | 20,604 | 22,616 | 21,951 | 21,387 | 22,861 | 21,672 | 20,591 | 20,442 | 24,845 | 22,677 | 20,441 | 18,887 | 16,868 | 15,536 | 13,398 | ||||||
Book value per share (BVPS)2 | 14.49 | 13.92 | 14.38 | 17.59 | 17.83 | 16.29 | 17.86 | 17.26 | 16.77 | 17.67 | 16.72 | 15.84 | 15.60 | 19.02 | 17.36 | 15.64 | 14.45 | 12.80 | 11.77 | 10.06 | ||||||
Share price1, 3 | 62.79 | 59.87 | 68.81 | 77.47 | 70.10 | 65.39 | 63.98 | 66.07 | 65.28 | 70.35 | 77.87 | 65.69 | 80.36 | 73.21 | 73.44 | 66.92 | 70.50 | 74.00 | 80.41 | 84.68 | ||||||
Valuation Ratio | ||||||||||||||||||||||||||
P/BV ratio4 | 4.33 | 4.30 | 4.79 | 4.40 | 3.93 | 4.02 | 3.58 | 3.83 | 3.89 | 3.98 | 4.66 | 4.15 | 5.15 | 3.85 | 4.23 | 4.28 | 4.88 | 5.78 | 6.83 | 8.42 | ||||||
Benchmarks | ||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||
Abbott Laboratories | 6.65 | 6.30 | 5.94 | 5.40 | 4.96 | 4.65 | 4.86 | 4.49 | 4.38 | 3.94 | 3.72 | 3.23 | 3.40 | 2.95 | 2.71 | 2.42 | 3.76 | 2.72 | 3.20 | 2.70 | ||||||
AbbVie Inc. | 14.18 | 10.93 | 11.31 | — | — | — | — | — | — | — | — | 44.74 | 36.95 | 22.43 | 18.89 | 21.33 | 21.24 | 14.80 | 19.21 | 21.77 | ||||||
Amgen Inc. | 14.53 | 11.57 | 13.67 | 14.33 | 13.84 | 11.47 | 10.37 | 9.92 | 9.41 | 8.56 | 8.35 | 7.41 | 5.02 | 3.98 | 4.05 | 3.91 | 4.14 | 3.51 | 4.27 | 4.16 | ||||||
Bristol-Myers Squibb Co. | 3.55 | 2.87 | 2.82 | 2.77 | 2.80 | 5.30 | 4.63 | 4.91 | 5.89 | 5.89 | 7.67 | 6.65 | 8.88 | 6.75 | 6.05 | 6.36 | 5.66 | 5.56 | 8.36 | 8.38 | ||||||
Eli Lilly & Co. | 35.07 | 26.02 | 35.12 | 47.73 | 51.67 | 31.28 | 39.03 | 46.37 | 12.87 | 8.58 | 8.96 | 6.18 | 7.33 | 6.20 | 6.49 | 6.43 | 6.33 | 5.28 | 6.25 | 5.55 | ||||||
Illumina Inc. | 15.36 | 9.09 | 11.38 | 9.70 | 9.43 | 9.62 | 10.16 | 11.58 | 11.43 | 12.15 | 14.64 | 11.30 | 11.79 | 10.48 | 10.67 | 10.71 | 10.95 | 9.03 | 11.90 | 10.48 | ||||||
Johnson & Johnson | 6.72 | 5.93 | 6.19 | 6.46 | 6.61 | 5.84 | 5.78 | 6.39 | 6.08 | 5.81 | 5.60 | 5.34 | 5.79 | 5.08 | 4.98 | 4.72 | 4.72 | 4.30 | 4.68 | 4.34 | ||||||
Merck & Co. Inc. | 7.46 | 6.97 | 7.47 | 7.43 | 7.83 | 7.87 | 7.82 | 7.31 | 7.79 | 5.88 | 5.44 | 4.54 | 4.30 | 3.96 | 4.31 | 4.35 | 4.51 | 3.78 | 4.01 | 3.42 | ||||||
Pfizer Inc. | 2.98 | 3.10 | 3.31 | 3.16 | 3.00 | 3.14 | 3.42 | 3.84 | 3.80 | 3.55 | 3.44 | 2.80 | 2.98 | 3.45 | 3.41 | 3.37 | 3.40 | 3.21 | 3.40 | 3.19 | ||||||
Regeneron Pharmaceuticals Inc. | 4.81 | 6.21 | 7.34 | 5.33 | 3.79 | 3.48 | 3.38 | 3.74 | 5.07 | 4.92 | 5.97 | 4.80 | 5.66 | 7.37 | 9.07 | 9.49 | 8.58 | 8.02 | 11.19 | 10.54 | ||||||
Vertex Pharmaceuticals Inc. | 6.30 | 6.66 | 9.42 | 10.23 | 10.23 | 9.57 | 9.09 | 9.36 | 10.68 | 14.56 | 16.73 | 16.56 | 20.14 | 21.11 | 23.25 | 19.64 | 18.42 | 18.42 | 24.79 | 21.23 | ||||||
Zoetis Inc. | 20.97 | 22.55 | 25.71 | 21.68 | 25.42 | 21.53 | 24.00 | 21.31 | 18.74 | 21.38 | 22.36 | 19.72 | 21.52 | 16.49 | 17.11 | 17.96 | 17.46 | 15.25 | 18.64 | 20.16 |
Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Data adjusted for splits and stock dividends.
2 Q4 2020 Calculation
BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= 18,202,000,000 ÷ 1,256,593,156 = 14.49
3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.
4 Q4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 62.79 ÷ 14.49 = 4.33
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Gilead Sciences Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then slightly increased from Q3 2020 to Q4 2020. |